Wendy McCarty, APRN
Nurse Practitioner · Shepherdsville, KYNPI 1508195298
Payments from drug & device makers
Across 214 payments — averaging $15.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$718
- Pfizer$393
- Novo Nordisk$326
- Lilly USA, LLC$260
- Amgen$206
- GSK$197
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,295100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 57 | $718 |
| Pfizer | 27 | $393 |
| Novo Nordisk | 21 | $326 |
| Lilly USA, LLC | 16 | $260 |
| Amgen | 12 | $206 |
| GSK | 13 | $197 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $173 |
| AstraZeneca(2 entities) | 8 | $127 |
| Boehringer Ingelheim | 8 | $118 |
| Vanda Pharmaceuticals Inc. | 3 | $107 |
| Medtronic | 3 | $78 |
| Abbott | 4 | $66 |
| Bayer | 3 | $59 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $58 |
| Axsome Therapeutics, Inc. | 3 | $57 |
| Exact Sciences | 4 | $55 |
| Merck | 3 | $44 |
| Astellas Pharma US Inc | 2 | $40 |
| Abiomed | 1 | $31 |
| Dynavax Technologies Corporation | 2 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Tolmar, Inc. | 2 | $28 |
| Johnson & Johnson | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Globus Medical | 1 | $15 |
How this compares
$3,307 in reported general payments places this provider in the 85th percentile of 1,918 nurse practitioner providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 124 | $90,130 |
| OzempicSemaglutide | 57 | $65,452 |
| EliquisApixaban | 31 | $44,298 |
| MounjaroTirzepatide | 29 | $34,661 |
| JardianceEmpagliflozin | 22 | $30,598 |
| JanuviaSitagliptin Phosphate | 20 | $29,095 |
| LinzessLinaclotide | 14 | $18,146 |
| Repatha SureclickEvolocumab | 21 | $14,692 |
| Repatha SyringeEvolocumab | 17 | $11,699 |
| XareltoRivaroxaban | 11 | $11,578 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 34 | $11,013 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $5,621 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,886 |
| VascepaIcosapent Ethyl | 13 | $4,785 |
| Duloxetine Hcl | 91 | $3,846 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $197 | $95,016136 claims |
| Novo NordiskOzempic, Levemir, Novolog | $326 | $69,20784 claims |
| PfizerEliquis | $393 | $44,29831 claims |
| Lilly USA, LLCMounjaro | $260 | $34,66129 claims |
| Boehringer IngelheimJardiance | $118 | $30,59822 claims |
| MerckJanuvia | $44 | $29,09520 claims |
| AbbVieLinzess, Synthroid | $718 | $19,35532 claims |
| Johnson & JohnsonXarelto | $23 | $11,57811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,918 nurse practitioner providers in Kentucky.
Other nurse practitioner in Shepherdsville
- Tarah WafzigShepherdsville$11K
- Rachael BradfordLexington$447K
- Tara MuddLouisville$243K
- Lee HaasLouisville$95K
- Ashley KnableLouisville$86K
- Christina BenningerLouisville$81K
- Courtney BowlingCampbellsville$47K
- Rebecca BraunerLouisville$40K
- Scott SeitzWinchester$34K
- Kristen KreinestEdgewood$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.